Amgen Inc. (Nasdaq: AMGN) has delivered a potentially important late-stage success in Sjögren’s disease, announcing that investigational dazodalibep produced a statistically significant and clinically meaningful improvement in systemic disease activity in the Phase 3 OASIZ 301 trial. The primary endpoint measured change at Week 48 on the EULAR Sjögren’s Syndrome Disease Activity Index, or ESSDAI, and Amgen said treatment-related improvements were visible as early as Week 4 and persisted through the end of the blinded study period.
The result is especially significant because Sjögren’s remains one of rheumatology’s major therapeutic gaps. Despite the disease’s ability to affect glands, joints, lungs, nerves and other organ systems, there is still no FDA-approved disease-modifying systemic medicine specifically indicated for Sjögren’s disease. Treatment has historically relied on symptomatic therapies and off-label immunomodulators selected according to individual manifestations.
Investors immediately treated the readout as meaningful. Amgen shares rose about 4% during September 22 trading after the announcement and ultimately closed at $410.24, up 4.34% for the session. The reaction is notable because Amgen disclosed only topline efficacy language rather than the actual numerical difference between dazodalibep and placebo, meaning the market rewarded the fact that OASIZ 301 succeeded before seeing the size of the treatment effect.
That missing information now becomes central. A statistically positive result establishes that dazodalibep has cleared an important Phase 3 hurdle, but the eventual commercial and competitive value will depend on how much systemic disease activity improved, how many patients achieved clinically meaningful responses, what happened to fatigue, dryness and joint symptoms, and how the safety profile compares with emerging rivals.
Why has Sjögren’s disease been so difficult for drug developers?
Sjögren’s is often reduced in public descriptions to dry eyes and dry mouth because the immune system attacks the lacrimal and salivary glands. That description captures only part of the disease. Patients can also experience severe fatigue, musculoskeletal pain and systemic involvement affecting several organs, while the severity and dominant manifestations vary substantially from one patient to another.
That heterogeneity has complicated clinical development for years. A therapy might meaningfully improve one biological component of Sjögren’s while producing only a modest change on a composite score if other manifestations respond poorly. Even ESSDAI, one of the field’s established systemic disease-activity measures, can behave differently depending on which organ domains are active and how reversible those manifestations are.
Placebo responses present another problem. Reuters cited William Blair analyst Matt Phipps as noting that Sjögren’s development has historically been challenging partly because placebo response can make it harder to separate an active drug from control. That context helps explain why investors reacted favourably to a Phase 3 win even before Amgen released the numerical treatment difference.
OASIZ 301 attempted to reduce some of this complexity by enrolling adults with moderate-to-severe systemic disease activity and an ESSDAI score of at least five. The registered trial enrolled 651 participants across 216 locations, providing a much larger and more geographically diverse test than the earlier Phase 2 programme.
How does dazodalibep work differently from conventional immunosuppression?
Dazodalibep is a non-antibody fusion protein designed to block CD40 ligand, or CD40L. The CD40-CD40L pathway helps coordinate communication between T cells, B cells and antigen-presenting cells, making it an important component of adaptive immune activation. By disrupting that signalling, dazodalibep is intended to suppress several cellular and antibody-driven processes involved in Sjögren’s rather than targeting only one downstream inflammatory mediator.
That mechanism already had clinical support before OASIZ 301. In a randomized Phase 2 study published in Nature Medicine, 74 patients with moderate-to-severe systemic disease activity experienced a least-squares mean ESSDAI improvement of 6.3 points with dazodalibep compared with 4.1 points with placebo at Day 169, a statistically significant difference. A separate 109-patient cohort characterized by high symptom burden but limited systemic involvement also met its primary endpoint on the patient-reported ESSPRI measure.
Those two populations became the basis of Amgen’s late-stage strategy. Rather than assuming every patient with Sjögren’s should be evaluated through the same clinical framework, the company split development between patients with substantial systemic organ activity and those whose dominant burden is dryness, fatigue and pain despite relatively limited systemic activity.
That distinction may ultimately determine how broad the commercial opportunity becomes.
Why could OASIZ 303 matter as much as the successful OASIZ 301 trial?
OASIZ 301 answers the systemic-disease question. OASIZ 303 addresses patients with moderate-to-severe symptom burden but comparatively low systemic disease activity. ClinicalTrials.gov lists 434 participants in the second Phase 3 study, which is evaluating dazodalibep against placebo with a particular focus on patient-reported symptoms.
Amgen expects OASIZ 303 to complete in the fourth quarter of 2026. Reuters reported that William Blair’s Phipps expects the company may need two positive late-stage studies to support an FDA filing and that Amgen is likely to clarify its regulatory strategy after the second readout.
More importantly, OASIZ 303 could show whether dazodalibep works across the two major ways Sjögren’s presents clinically. A patient with active systemic organ disease may be judged primarily by ESSDAI, while another patient can experience debilitating dryness, pain and fatigue without accumulating a high systemic activity score.
If both Phase 3 populations succeed, Amgen could potentially argue that the drug addresses Sjögren’s across a wider clinical spectrum. If OASIZ 303 fails, dazodalibep could still retain value in systemic disease, but its practical addressable population and differentiation would become narrower.
That makes the next trial more than regulatory redundancy. It tests whether CD40L inhibition improves the symptoms patients commonly feel most intensely, not only the disease activity physicians can score across organ systems.
How much does the missing OASIZ 301 effect size matter?
Quite a lot.
Amgen said the primary endpoint was both statistically significant and clinically meaningful, but it did not disclose the Week 48 placebo-adjusted ESSDAI change, response rates or numerical results for key secondary endpoints. The company said detailed findings will be presented at an upcoming medical meeting.
The trial evaluated secondary measures covering dryness, tender and swollen joints, fatigue and an ESSDAI response defined as a reduction of at least five points from baseline. Those data will help determine whether the benefit is broad or concentrated in certain components of the disease.
Safety disclosure was similarly limited. Reuters reported that Amgen characterized most adverse events as mild to moderate and said few patients discontinued treatment because of adverse events, but full numerical safety data have not yet been presented publicly.
This is why investors should distinguish between trial success and competitive strength. The primary endpoint tells the market that dazodalibep works under the statistical framework of OASIZ 301. It does not yet reveal whether the benefit is large enough to become the preferred treatment once competing products are available.
Is Novartis actually ahead in the race to the first targeted Sjögren’s therapy?
Amgen is not developing dazodalibep into an empty pipeline.
Novartis reported in August 2025 that both of its global Phase 3 NEPTUNUS trials of ianalumab met their primary endpoints in Sjögren’s disease. Ianalumab has a different mechanism from dazodalibep: it is designed both to deplete B cells and inhibit BAFF receptor signalling, thereby reducing B-cell activation and survival. The FDA granted ianalumab Breakthrough Therapy Designation in January 2026, and Novartis said it planned global regulatory submissions beginning in 2026.
That means Amgen’s claim is not that dazodalibep is the first successful Phase 3 Sjögren’s drug. Novartis has already produced two positive pivotal studies and could reach regulators sooner.
The competitive question is therefore likely to become one of differentiation. If ianalumab reaches the market first, Amgen will need data demonstrating why CD40L inhibition offers a compelling alternative. The answer could involve efficacy magnitude, speed of response, symptom improvement, dosing, safety or effectiveness in specific patient populations.
Amgen’s observation that improvement began as early as Week 4 may become relevant here, particularly if detailed data show a clear early separation from placebo. But without the actual numerical curves, it is too soon to conclude that speed will be a competitive advantage.
How does Johnson & Johnson make the emerging market even more complicated?
Johnson & Johnson is developing nipocalimab, an FcRn blocker designed to reduce pathogenic IgG autoantibodies while preserving other components of immune function. The company has already moved the drug into Phase 3 Sjögren’s development after a Phase 2 programme showed reductions in disease activity and patient-reported symptoms.
Its Phase 3 programme uses change in clinical ESSDAI at Week 48 as the primary endpoint and has completed enrollment, although the registered study extends considerably beyond 2026.
This creates an unusually diverse competitive landscape. Amgen is interrupting CD40L signalling between immune cells. Novartis is attacking B-cell survival through BAFF-R while depleting B cells. Johnson & Johnson is reducing pathogenic IgG through FcRn blockade.
If more than one programme succeeds, Sjögren’s could move rapidly from having no approved targeted systemic therapy to supporting several mechanistically distinct medicines.
That would force physicians to answer a question the field has rarely been in a position to ask: which immune pathway should be targeted for which patient?
Could biomarkers eventually split Sjögren’s into treatment subgroups?
The heterogeneity that made Sjögren’s difficult for drug development may eventually become an opportunity for precision treatment.
Johnson & Johnson has reported exploratory analyses suggesting patients with higher autoantibody and IgG levels may experience greater responses to nipocalimab, consistent with its antibody-lowering mechanism. Those findings remain exploratory but demonstrate the type of biological segmentation companies are beginning to investigate.
Dazodalibep could develop its own response profile. Blocking CD40L affects T-cell and B-cell interaction more broadly, meaning particular immunological patterns might eventually identify patients more likely to benefit.
OASIZ 301’s detailed biomarker analyses will therefore matter beyond explaining the average treatment effect. If Amgen can identify biological characteristics linked to strong responses, it may be able to differentiate dazodalibep even in a market containing several effective therapies.
This is where the Sjögren’s field could begin resembling other autoimmune markets, where multiple approved mechanisms coexist because no single drug works best for every patient.
Why does this result matter to Amgen’s $27.8 billion Horizon Therapeutics acquisition?
Dazodalibep entered Amgen through the company’s 2023 acquisition of Horizon Therapeutics, a transaction valued at approximately $27.8 billion. The deal was primarily justified by commercial rare-disease assets including Tepezza, Krystexxa and Uplizna, but Horizon also brought pipeline programmes including dazodalibep.
The acquired pipeline has therefore become an additional test of whether Amgen can extract long-term value from the transaction beyond the products already generating revenue.
A successful Sjögren’s franchise would strengthen that argument because dazodalibep addresses a much broader autoimmune population than many traditional ultra-rare disease products. It could also leverage Amgen’s established inflammation and specialty-medicine infrastructure.
The opposite scenario would matter as well. Large pharmaceutical acquisitions are increasingly judged not only by the sales of acquired products but by whether purchased research programmes mature into new franchises. A Phase 3 win therefore adds strategic value that extends beyond the immediate Sjögren’s market.
What does the Amgen share-price reaction tell investors?
Amgen shares closed September 22 at $410.24, up 4.34% from the previous session after trading as high as $413. The stock had closed at $393.16 one day earlier, meaning the Phase 3 announcement coincided with approximately $17 of additional value per share during the session.
Reuters reported that the shares were up roughly 4% during morning trading and attributed the move to investor enthusiasm around the positive readout.
That response looks particularly notable because the topline release omitted many details analysts normally use to model a future drug. The market appears to have assigned value to clinical de-risking itself, reflecting the difficulty of succeeding in Sjögren’s and the absence of an approved systemic therapy specifically for the disease.
Sentiment should nevertheless remain conditional. Full efficacy and safety data, the OASIZ 303 result, regulatory discussions and Novartis’ progress with ianalumab could all materially alter how investors value dazodalibep.
What would turn the Phase 3 win into a major new autoimmune franchise?
Three things now matter most.
First, Amgen needs the full OASIZ 301 dataset to show a persuasive effect size rather than merely statistical significance. Clinicians will want to see how many patients achieved meaningful systemic improvement, which organ domains responded, whether patient-reported symptoms changed and whether the safety profile supports prolonged treatment.
Second, OASIZ 303 needs to establish whether dazodalibep can help patients whose greatest burden is dryness, fatigue and pain rather than overt systemic organ activity. That population could materially widen the product’s clinical relevance.
Third, Amgen needs to position the medicine against a competitive field that is moving unusually quickly. Novartis already has two positive Phase 3 trials for ianalumab, while Johnson & Johnson is pursuing a different antibody-focused mechanism with nipocalimab.
The significance of OASIZ 301 is therefore not that Amgen has won the Sjögren’s race. It is that the company has now earned a place in what could become one of autoimmune medicine’s most important newly created treatment markets.
For patients, that competition would be overdue. Sjögren’s has spent decades in the uncomfortable position of being common enough to affect large numbers of people yet therapeutically underserved enough that physicians still rely heavily on symptomatic and off-label treatment.
Dazodalibep’s Phase 3 success suggests that could finally change. But the headline Amgen released on September 22 leaves one crucial number hidden: how much better was the drug than placebo? Until those detailed data arrive, the trial has established that dazodalibep works. The next question is whether it works well enough to beat the therapies racing toward the same market.
